<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519714</url>
  </required_header>
  <id_info>
    <org_study_id>PNAI-MNA-001</org_study_id>
    <nct_id>NCT00519714</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Medical Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique des maladies lipidiques de Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de médecine genique communautaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omnispec clinical research Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manna Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jerome Medical Research Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Victoria Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hotel Dieu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Michael's Hospital Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Cardiac Care Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maritime Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhodin Recherche Clinique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Line Medical Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research, Vancouver General Hosp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Allin Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Paul's Hospital Healthy Heart Clinical Trial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clinical Trials Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Recherche Invascor Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MSHJ Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr.Kim W Tan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study. Following a
      6-8 week placebo and dietary-controlled baseline period, approximately 195 men and women with
      either hypertriglyceridemia or mixed hyperlipidemia with serum triglycerides (TG) &gt; 200 mg/dl
      (2.26 mmol/l) will be randomized to receive either placebo, 30 mg 1-MNA or 90 mg 1-MNA three
      times daily for twelve weeks. Lipid and ancillary exploratory parameters will be evaluated at
      screening, during the baseline period, upon randomisation and throughout the 12-week active
      treatment period. Additionally, blood samples will be drawn at randomisation and at clinic
      visits during the active treatment period for sparse sampling population pharmacokinetic
      assessments. All blood samples for lipid assessments and glucose measurements will be
      collected following a 12-hour fast. Safety and tolerability will be assessed throughout the
      trial through the evaluation of physical exams, ECGs, routine hematology and blood chemistry
      testing, and adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change in total serum Triglycerides from baseline to end of study</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent change in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol , total apolipoprotein B , apolipoprotein A1 and TG/HDL-C ratio from baseline to end of study.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three placebo capsules PO three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-MNA 270 mg daily: three active treatment capsules PO three times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1-Methylnicotinamide (1-MNA)</intervention_name>
    <description>Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>1-MNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 18 years of age at the time of informed consent (women of
             childbearing potential must be practicing adequate contraception)

          -  Patients with mean serum TG &gt; 200 mg/dl (2.26 mmol/l) and &lt; 700 mg/dl (7.91 mmol/l) as
             measured at 2 sequential visits during the dietary controlled baseline period (Visits
             2 and 3 or Visits 3 and 3a) and having lower level within 25% of upper level (higher
             value minus lower value)/higher value &lt; 0.25)

          -  Patients willing and able to sign an informed consent form and follow the protocol

        Exclusion Criteria:

          -  Patients who are pregnant or nursing

          -  Patients with evidence of hepatic (ALT or AST greater than 1.5 ULN, bilirubin greater
             than 1.5 ULN, or cirrhosis) or renal dysfunction (serum creatinine greater than 140
             μmol/l, or nephrotic syndrome) as measured during the baseline phase

          -  Patients with uncontrolled diabetes mellitus (fasting glucose level above 11 mmol/l or
             HbA1C above 10%) as measured during the baseline phase

          -  Patients with hypothyroidism that is not treated or not stable for at least 6 months
             prior to study entry

          -  Patients with uncontrolled hypertension (systolic blood pressure above 160 mm Hg
             and/or diastolic blood pressure above 110 mm Hg)

          -  Patients with systolic blood pressure above 140 mm Hg AND three or more of the
             following cardiovascular risk factors:

               -  Current cigarette smoker

               -  HDL-C &lt; 40 mg/dL (1.04 mmol/L)

               -  Coronary heart disease in male first degree relative &lt; 55 years of age

               -  Coronary heart disease in female first degree relative &lt; 65 years of age

               -  Male age 45 years or older

               -  Female age 55 years or older

          -  Patients with known hyperuricemia or with a history of gout

          -  Patients with an active peptic ulcer

          -  Patients with known coronary artery disease, cerebrovascular disease or peripheral
             arterial disease that has previously required PCI or surgical intervention

          -  Patients with known intolerance or allergy to niacin

          -  Patients consuming more than 10 alcoholic drinks per week

          -  Patients with a history of drug abuse

          -  Patients receiving any lipid modifying agent within 4 weeks of entry into the baseline
             period

          -  Patients participating in another clinical trial within 30 days of entry into the
             baseline period

          -  Patients considered to be non-compliant to study medication (&lt; 80% study medication)
             or diet during the placebo-baseline phase

          -  Patients for whom the investigator determines that the study would not be appropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>June 18, 2010</last_update_submitted>
  <last_update_submitted_qc>June 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jean-Claude Tardif/Researcher</name_title>
    <organization>Montreal Heart Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

